MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 599225 | Name: Loracarbef hydrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Loracarbef hydrate is a 1-carbacephem antibiotic; has a broad spectrum of antimicrobial activity; carbacephems differ from cephalosporins in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring.

Chemical Structure

Loracarbef hydrate
Loracarbef hydrate
CAS#121961-22-6

Theoretical Analysis

MedKoo Cat#: 599225

Name: Loracarbef hydrate

CAS#: 121961-22-6

Chemical Formula: C16H18ClN3O5

Exact Mass:

Molecular Weight: 367.78

Elemental Analysis: C, 52.25; H, 4.93; Cl, 9.64; N, 11.43; O, 21.75

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
LY 163892 monohydrate; LY-163892 monohydrate; LY163892 monohydrate; Loracarbef hydrate; Lorabid;
IUPAC/Chemical Name
(6R,7S)-7-(2-amino-2-phenylacetamido)-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate
InChi Key
GPYKKBAAPVOCIW-QRVSAPIOSA-N
InChi Code
InChI=1S/C16H16ClN3O4.H2O/c17-9-6-7-10-12(15(22)20(10)13(9)16(23)24)19-14(21)11(18)8-4-2-1-3-5-8;/h1-5,10-12H,6-7,18H2,(H,19,21)(H,23,24);1H2/t10-,11?,12+;/m1./s1
SMILES Code
O=C(C(N12)=C(Cl)CC[C@]2([H])[C@H](NC(C(N)C3=CC=CC=C3)=O)C1=O)O.[H]O[H]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 367.78 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Hyslop DL. Efficacy and safety of loracarbef in the treatment of pneumonia. Am J Med. 1992 Jun 22;92(6A):65S-69S. Review. PubMed PMID: 1621747. 2: Gooch WM 3rd, Adelglass J, Kelsey DK, Masica D, Johns D Jr, Weinberg BC. Loracarbef versus clarithromycin in children with acute otitis media with effusion. Clin Ther. 1999 Apr;21(4):711-22. PubMed PMID: 10363736. 3: McCarty J. Loracarbef versus penicillin VK in the treatment of streptococcal pharyngitis and tonsillitis in an adult population. Am J Med. 1992 Jun 22;92(6A):74S-79S. PubMed PMID: 1621750. 4: McCarty J, Hernon Y, Linn L, Therasse DG, Molina A, Bleile N. Loracarbef versus penicillin VK in the treatment of streptococcal pharyngitis and tonsillitis in adults. Clin Ther. 1992 Jan-Feb;14(1):30-40. PubMed PMID: 1576624. 5: Hyslop DL, Bischoff W. Loracarbef (LY163892) versus cefaclor and norfloxacin in the treatment of uncomplicated pyelonephritis. Am J Med. 1992 Jun 22;92(6A):86S-94S. PubMed PMID: 1621752. 6: Hyslop DL, Jacobson K, Guerra FJ. Loracarbef (LY163892) versus amoxicillin/clavulanate in bronchopneumonia and lobar pneumonia. Clin Ther. 1992 Mar-Apr;14(2):254-67. PubMed PMID: 1611648. 7: Müller O, Spirer Z, Wettich K. Loracarbef versus penicillin V in the treatment of streptococcal pharyngitis and tonsillitis. Infection. 1992 Sep-Oct;20(5):301-8. PubMed PMID: 1428189. 8: Zeckel ML, Jacobson KD, Guerra FJ, Therasse DG, Farlow D. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute bacterial exacerbations of chronic bronchitis. Clin Ther. 1992 Mar-Apr;14(2):214-29. PubMed PMID: 1611645. 9: Roller S, Lode H, Stelzer I, Deppermann KM, Boeckh M, Koeppe P. Pharmacokinetics of loracarbef and interaction with acetylcysteine. Eur J Clin Microbiol Infect Dis. 1992 Sep;11(9):851-5. PubMed PMID: 1468429. 10: Disney FA, Hanfling MJ, Hausinger SA. Loracarbef (LY163892) vs. penicillin VK in the treatment of streptococcal pharyngitis and tonsillitis. Pediatr Infect Dis J. 1992 Aug;11(8 Suppl):S20-6. PubMed PMID: 1513608. 11: Müller O, Wettich K. Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia. Infection. 1992 May-Jun;20(3):176-82. Erratum in: Infection 1992 Sep-Oct;20(5):308. PubMed PMID: 1463527. 12: Force RW, Nahata MC. Loracarbef: a new orally administered carbacephem antibiotic. Ann Pharmacother. 1993 Mar;27(3):321-9. Review. PubMed PMID: 8453172. 13: Foshee WS. Loracarbef (LY163892) versus amoxicillin-clavulanate in the treatment of bacterial acute otitis media with effusion. J Pediatr. 1992 Jun;120(6):980-6. PubMed PMID: 1593361. 14: Dere WH, Farlow D, Therasse DG, Jacobson KD, Guerra FJ. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute purulent bacterial bronchitis. Clin Ther. 1992 Mar-Apr;14(2):166-77. PubMed PMID: 1611641. 15: Dere WH, Farlow D, Therasse DG, Ruoff GE. Loracarbef (LY163892) versus cefaclor in the treatment of acute bacterial bronchitis. Clin Ther. 1992 Jan-Feb;14(1):41-53. PubMed PMID: 1576625. 16: Nord CE, Grahnen A, Eckernäs SA. Effect of loracarbef on the normal oropharyngeal and intestinal microflora. Scand J Infect Dis. 1991;23(2):255-60. PubMed PMID: 1853174. 17: Hanfling MJ, Hausinger SA, Squires J. Loracarbef vs. cefaclor in pediatric skin and skin structure infections. Pediatr Infect Dis J. 1992 Aug;11(8 Suppl):S27-30. PubMed PMID: 1513609. 18: Bapujee AT, Singh T, Ahmed T, Monif T, Saha N, Sharma PL. The effect of four different types of diet on the bioavailability of loracarbef. Eur J Drug Metab Pharmacokinet. 2007 Oct-Dec;32(4):205-11. PubMed PMID: 18348469. 19: Bandak SI, Turnak MR, Allen BS, Bolzon LD, Preston DA. Assessment of the susceptibility of Streptococcus pneumoniae to cefaclor and loracarbef in 13 countries. J Chemother. 2000 Aug;12(4):299-305. PubMed PMID: 10949979. 20: Arguedas AG, Arrieta AC, Stutman HR, Akaniro JC, Marks MI. In-vitro activity of cefprozil (BMY 28100) and loracarbef (LY 163892) against pathogens obtained from middle ear fluid. J Antimicrob Chemother. 1991 Mar;27(3):311-8. PubMed PMID: 1903788.

View History

Tranilast

Tranilast

New Featured